BioTime, Inc. (BTX) Analysts See $-0.06 EPS

February 15, 2018 - By Marry Poplack

 BioTime, Inc. (BTX) Analysts See $ 0.06 EPS
Investors sentiment decreased to 1.96 in Q3 2017. Its down 0.17, from 2.13 in 2017Q2. It is negative, as 9 investors sold BioTime, Inc. shares while 15 reduced holdings. 9 funds opened positions while 38 raised stakes. 49.13 million shares or 2.79% more from 47.80 million shares in 2017Q2 were reported.
Gluskin Sheff And Associate holds 0% of its portfolio in BioTime, Inc. (NYSEAMERICAN:BTX) for 11,800 shares. Nationwide Fund Advsr holds 0% in BioTime, Inc. (NYSEAMERICAN:BTX) or 83,563 shares. State Street has 1.36 million shares for 0% of their portfolio. Berson And Corrado Inv Advsr Limited Liability has invested 0.12% in BioTime, Inc. (NYSEAMERICAN:BTX). Bnp Paribas Arbitrage Sa has 0% invested in BioTime, Inc. (NYSEAMERICAN:BTX). Regent Investment Management Llc has 22,500 shares. Douglass Winthrop Advisors Ltd Llc owns 10,000 shares. Scotia Cap has invested 0% of its portfolio in BioTime, Inc. (NYSEAMERICAN:BTX). California Pub Employees Retirement invested in 48,400 shares. Geode Capital Ltd Liability Com holds 0% or 1.07M shares. State Board Of Administration Of Florida Retirement Systems reported 22,784 shares. Moreover, Citadel Advsr Limited Liability Company has 0% invested in BioTime, Inc. (NYSEAMERICAN:BTX). Group One Trading Ltd Partnership invested 0% of its portfolio in BioTime, Inc. (NYSEAMERICAN:BTX). Citigroup reported 2,661 shares stake. 200 are held by Huntington National Bank & Trust.

Since October 13, 2017, it had 1 buying transaction, and 0 selling transactions for $7.00 million activity.

Analysts expect BioTime, Inc. (NYSEAMERICAN:BTX) to report $-0.06 EPS on March, 15.After having $-0.05 EPS previously, BioTime, Inc.’s analysts see 20.00 % EPS growth. The stock decreased 1.13% or $0.03 during the last trading session, reaching $2.62. About 218,590 shares traded. BioTime, Inc. (NYSEAMERICAN:BTX) has risen 22.71% since February 15, 2017 and is uptrending. It has outperformed by 6.01% the S&P500.

BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies. The company has market cap of $332.39 million. The Company’s product candidates include Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV related facial lipoatrophy; OpRegen, which is in Phase I/IIa clinical trial for the treatment of the dry form of age-related macular degeneration; HyStem-BDNF, a preclinical development program for the delivery of recombinant human brain-derived neurotrophic factor directly into the stroke cavity of patients for aiding in tissue repair and functional recovery; and ReGlyde that is in preclinical development as a device for viscosupplementation and a combination product for drug delivery in osteoarthritis. It has a 6.09 P/E ratio. The firm also develops AST-OPC1, a therapy derived from pluripotent stem cells that is in a Phase I/IIa clinical trial for spinal cord injuries; AST-VAC1, a patient-specific cancer immunotherapy that is in Phase II clinical trial for acute myeloid leukemia; and AST-VAC2, a non-patient specific cancer immunotherapy, which is in Phase I/IIa clinical trial to treat non-small cell lung cancer.

More recent BioTime, Inc. (NYSEAMERICAN:BTX) news were published by: which released: “Data From the Successful Pivotal Trial to Be Presented at the IMCAS Conference” on January 29, 2018. Also published the news titled: “BioTime to Participate at the BIO CEO and Investor Conference in New York …” on February 07, 2018.‘s news article titled: “and Vision Restoration Programs to Be Presented at ARVO 2018” with publication date: February 15, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.